Published by Josh White on 29th October 2018
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the latest key research findings for its 'Nuvec' delivery system on Monday, reporting that the Nuvec particles had a "clear adjuvant effect" to help deliver a level of immune response for both the mRNA and pDNA OVA antigens, comparable to that of existing delivery systems.